Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Accepted on 27 May 2025

Outcomes and prognostic factors of alternative treatment regimens for angioimmunoblastic T-cell lymphoma: a retrospective analysis

in Cancer Molecular Targets and Therapeutics

Jiaqin Yan
Jiebing Wang
Junhui Zhang
Xudong Zhang
Lei Zhang
Mingzhi Zhang
Zunmin Zhu

Frontiers in Oncology

doi 10.3389/fonc.2025.1585013

141 views

Original Research

Published on 27 May 2025

Molecular and clinical insights into HIV-associated and HIV-negative aggressive B-cell lymphomas: prognostic quantitative biomarker analysis and therapeutic implications

in Cancer Molecular Targets and Therapeutics

Liming Liu
Tianwa Wang
Jiping Luo
Jianrong Huang
Kaipeng Huang
Kun Chen
Chao Wang
Zhiqiang Cheng

Frontiers in Oncology

doi 10.3389/fonc.2025.1603801

776 views

Original Research

Published on 27 May 2025

Preparation of RGD-modified liposomes encapsulated with shikonin and its targeted anti-melanoma effects

in Cancer Molecular Targets and Therapeutics

Hao Zhang
Ying Zhao
Tingting Chen
Xinliang Mao
Jiping Li
Li Fan
Min Li
Xianchun Wen

Frontiers in Oncology

doi 10.3389/fonc.2025.1573628

760 views

Original Research

Published on 26 May 2025

Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo

in Cancer Molecular Targets and Therapeutics

Summya Rashid

Frontiers in Oncology

doi 10.3389/fonc.2025.1572095

876 views

Original Research

Published on 23 May 2025

Upregulation of stomatin is associated with poor prognosis and promotes tumor progression of orbital diffuse large B-cell lymphoma

in Cancer Molecular Targets and Therapeutics

Wen Chen
Jingyi Chi
Weichen Song
Xiuyun Li
Jinlei Ma
Xinyu Liu
Lihua Xiao
Wenwen Zhu

Frontiers in Oncology

doi 10.3389/fonc.2025.1596614

922 views

Original Research

Accepted on 22 May 2025

Prognostic Alternative mRNA Splicing in Lung Adenocarcinoma

in Cancer Molecular Targets and Therapeutics

Panke Su
Pei Xu
Deying Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1579017

176 views

Original Research

Published on 22 May 2025

CD46 TREM1 regulates the autophagy marker LC3B ATG5 in oral squamous cell carcinoma

in Cancer Molecular Targets and Therapeutics

Xiaodan Liu
Fumin Zheng
Meihua Gao
Yuanfei Wang
Xiaofang Lv
Beibei Cong
Wanchun Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1579282

923 views

Original Research

Published on 22 May 2025

Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin

in Cancer Molecular Targets and Therapeutics

Xianghua Quan
Jing Li
Jialin Sun
Xiaomin Xing
Donghua Liu
Hongyan Ji
Qie Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1564681

765 views

Original Research

Published on 19 May 2025

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

in Cancer Molecular Targets and Therapeutics

Yvonne A. Evrard
Sergio Y. Alcoser
Michael Mullendore
Li Chen
Chih-Jian Lih
Vishnuprabha Rahul Kannan
Vivekananda Datta
Lindsay Dutko
Shahanawaz Jiwani
Lawrence V. Rubinstein

Frontiers in Oncology

doi 10.3389/fonc.2025.1571635

1,144 views

Original Research

Published on 16 May 2025

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

in Cancer Molecular Targets and Therapeutics

Ying Jin
Ping Sun
Peng Chen
Yuqiang Xu
Guangmao Mu
Zhengxia Zha
Simin Wu
Meixia Fu
Hao Jiang
Sheng Huang

Frontiers in Oncology

doi 10.3389/fonc.2025.1533059

1,872 views

Perspective

Published on 15 May 2025

Bringing value to cancer research

in Cancer Molecular Targets and Therapeutics

Casey J. Allen
Horn M. Danea
Fabrice Smieliauskas
Stephen Edge
Rachel A. Greenup

Frontiers in Oncology

doi 10.3389/fonc.2025.1580575

699 views

Review

Published on 15 May 2025

Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma

in Cancer Molecular Targets and Therapeutics

Ziman Wu
Haiyan Yang
Xinying Li
Xiang Ji
Chan Mo
Zhou Zheng
Yafei Xu
Dan Xiong

Frontiers in Oncology

doi 10.3389/fonc.2025.1520733

1,000 views

Review

Published on 14 May 2025

Role of exosomes in castration-resistant prostate cancer

in Cancer Molecular Targets and Therapeutics

Yuan Cao
Jianjun Wang
Huiwen Luo
Yaodong Wang
Xianfu Cai
Tiansheng Zhang
Yougang Liao
Decai Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1498733

1,041 views

Original Research

Published on 13 May 2025

Pan-cancer analysis reveals TRA16 as a master regulator of human carcinogenesis

in Cancer Molecular Targets and Therapeutics

Yanyan Zhu
Yike Gao
Xiaoqing Huang
Bowang Chen
Xinyi Wang
Ying Wu
Jian Sun
Xiaoyun Huang

Frontiers in Oncology

doi 10.3389/fonc.2025.1543419

1,253 views

Review

Published on 13 May 2025

Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment

in Cancer Molecular Targets and Therapeutics

Maryamosadat Mavaei
Simin Farokhi
Mohammad Hasan Yousefi
Arshia Fakouri
Alireza Shadab
Mohammad Hossein Abdolmohammadi
Faranak Fallahian
Hamed Afkhami

Frontiers in Oncology

doi 10.3389/fonc.2025.1533065

1,237 views

Original Research

Published on 12 May 2025

RACGAP1 and MKI67 are potential prognostic biomarker in hepatocellular carcinoma caused by HBV/HCV via lactylation

in Cancer Molecular Targets and Therapeutics

Muhammad Muddasar Saeed
Xinying Ma
Xinyu Fu
Ikram Ullah
Tanveer Ali
Changchuan Bai
Ying Liu
Chengyong Dong
Xiaonan Cui

Frontiers in Oncology

doi 10.3389/fonc.2025.1537084

1,944 views
1 citation